Announcements Trials
Browse Landscape

Status

Approved for marketing 2

Sponsor Class

OTHER 2

Study Type

Interventional 1409Observational 24Expanded_access 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Wounds and Injuries 1Pancreatic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

regorafenib 3Sunitinib 2Ramucirumab 2Oxaliplatin 2Fluorouracil 2zenocutuzumab 1zanidatamab 1ulixertinib 1trifluridine tipiracil drug combination 1sodium thiosulfate 1selpercatinib 1ripretinib 1peginterferon alfa-2a 1pegilodecakin 1onvansertib 1omburtamab I-131 1guselkumab 1futibatinib 1derazantinib 1balstilimab 1avapritinib 1Tenofovir 1Taxes 1Proton Pump Inhibitors 1Paclitaxel 1Melphalan 1Leucovorin 1Laparoscopy 1Imatinib Mesylate 1IMM-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Oxaliplatin × Gastrointestinal × Clear all
NCT02436044 2019-08-20

HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC

Sun Yat-sen University

Approved for marketing
Gastrointestinal

Carcinoma, Hepatocellular, Wounds and Injuries

NCT00786058 2009-06-15

A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

CONKO-Studiengruppe

Approved for marketing
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡